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Key Points 
 
1. ACTN1 mutations were identified in 10 of 239 families with inherited thrombocytopenia of 
unknown origin. 
2. ACTN1-related thrombocytopenia is characterized by mild thrombocytopenia with platelet 
macrocytosis and low risk of bleeding. 
 
 
 
Abstract 
 
Inherited thrombocytopenias (ITs) are a heterogeneous group of syndromic and non syndromic 
diseases caused by mutations affecting different genes. Alterations of ACTN1, the gene encoding for 
α-actinin 1, have recently been identified in a few families as responsible for a mild form of IT (ACTN1-
related thrombocytopenia; ACTN1-RT). To better characterize this disease, we screened ACTN1 in 128 
probands and found ten (eight novel) missense heterozygous variants in 11 families. Combining 
bioinformatics, segregation, and functional studies we demonstrated that all but one amino acid 
substitution had deleterious effects. The clinical and laboratory findings of 31 affected individuals 
confirmed that ACTN1-RT is a mild macrothrombocytopenia with low risk of bleeding. Low reticulated 
platelet counts and only slightly increased serum thrombopoietin levels indicated that the latest 
phases of megakaryopoiesis were affected. Given its relatively high frequency in our cohort (4.2%), 
ACTN1-RT has to be taken into consideration in the differential diagnosis of ITs. 
  
Introduction 
 
Inherited thrombocytopenias (IT) are a highly heterogeneous group of diseases characterized by 
different degrees of severity and complexity.1 The variable clinical phenotype derives from a wide 
genetic heterogeneity, at least 22 genes having been identified so far.2-4 Moreover, mutations in 
known genes account for only 50% of patients, indicating that not all the existing forms have yet been 
identified. One of the most recently recognized disorders is ACTN1-related thrombocytopenia 
(ACTN1-RT), an autosomal dominant form caused by mutations in the gene (ACTN1) encoding for one 
of the two non-muscle isoforms of α-actinin 1.5 Mainly expressed in megakaryocytes and platelets,2 
ACTN1 has a binding domain for cross-linking the actin filaments into bundles. Based on the seven 
families described in the literature, ACTN1-RT is characterized by mild macrothrombocytopenia and 
bleeding tendency and no additional defects associated with low platelet count.5,6 To better 
characterize ACTN1-RT, we studied ten families identified after the screening of ACTN1 in 128 
probands with an IT of unknown origin. 
 
Research design  
 
Of 239 consecutive probands with IT examined at the IRCCS Policlinico San Matteo Foundation, (Pavia, 
Italy), we enrolled all the 128 propositi without a certain diagnosis after the IT diagnostic work-up.7,8 
Mutational screening of ACTN1 was carried out by whole exome sequencing (WES) in seven 
individuals and Sanger sequencing in the remaining 121 probands, as indicated in Table 1S. 
Pathogenetic effects of variants were investigated by segregation analysis, bioinformatic tools, and 
immunofluorescence studies (Tables 1S; Figures 1 and 1S). Medical history (family history included), 
bleeding tendency, and outcome of possible surgeries and pregnancies were ascertained from 
medical records or patient interviews. 
 
 
Results and Discussion 
 
Characterization of ACTN1 missense variants 
  
Mutational screening of ACTN1 identified ten different missense variants in 11 out of 128 probands 
(Table 1S). Whereas two (p.Arg738Trp and p.Arg752Gln) were known mutations,5 the others were 
novel variants not enlisted in dbSNP databases. Interestingly, c.136C>T (p.Arg46Trp) was found in two 
families and affected the same residue hit by the known c.137G>A (p.Arg46Gln) mutation.5,6 The eight 
novel variants affected highly conserved amino acid residues (data not shown) and different 
pathogenicity prediction tools indicated deleterious effects. All but one (p.Asp666Val) of the variants 
segregated with thrombocytopenia within pedigrees when family members were available (Figure 
1S). 
In order to determine the pathogenetic role of the novel missense variants, we performed 
immunofluorescence analysis in human fibroblasts (Figure 1A). Transfecting wild type constructs, we 
observed that the cytoskeleton was organized in filaments, with ACTN1 colocalizing with actin. In cells 
expressing all but one (p.Asp666Val) of the mutations, ACTN1 was instead distributed uniformly 
within the cytoplasm and actin was no longer organized in filaments. Consistent with segregation 
analysis, the correct organization of the cytoskeleton in cells expressing p.Asp666Val excluded this 
variant as a disease-causing mutation. It is worth noting that p.Asp666Val is outside the actin binding 
(ABD) and calmodulin-like (CaM) domains (Figure 1B), suggesting that only alterations of these 
functional regions are compatible with the disease.  
 
ACTN1-RT as a mild form of thrombocytopenia with slight platelet macrocytosis 
Of the ten families with pathogenetic variants, nine were from Italy and one from United Kingdom. Of 
the 31 affected family members, 22 were females and nine males, indicating a potential diagnostic 
ďias due to ŵeŶorrhagia. At the tiŵe of reĐogŶitioŶ of throŵďoĐytopeŶia, the patieŶts’ ŵeaŶ age was 
34.5 years (range, 3-82 years). Mean platelet count was slightly reduced (10326x109/L) with only one 
subject having a platelet count lower than the cut off value (50x109/L) for safe platelet count (Table 
1).9 Of note, two young girls (families 5 and 8) had a platelet count slightly above 150x109/L, but they 
were considered as thrombocytopenic according to the age- and gender-specific reference intervals in 
the Italian population.10 Both mean platelet volume (12.61.7 fL; 95% CI 12.0-13.2) and diameter 
(3.20.5 m; 95% CI 3.0-3.4) were significantly higher in ACTN1-RT than in 50 controls, where values 
were 10.11.4 fL (95% CI 9.7-10.4) and 2.40.3 m (95% CI 2.3-2.5), respectively. 
The mean reticulated platelet count evaluated in nine patients using a hematology analyzer was lower 
  
(1.160.64x109/L; 95% CI 0.48-2.07) than in 15 controls (4.30.96x109/L; 95% CI 3.55-5.24), indicating 
that thrombocytopenia derived from reduced platelet formation. To further investigate this aspect, 
we measured the serum thrombopoietin (TPO) concentration, which is inversely related to the total 
megakaryocyte and platelet mass,11 with a commercially available ELISA kit (Quantikine Human TPO 
Immunoassay, R&D). The mean TPO level was slightly higher (22.36.5 pg/mL, 95% CI 13.1-31.5) in 
the 14 examined patients than in controls (n=40; 14.610.8 pg/mL; 95% CI 11.1-18.0), suggesting 
normal megakaryopoiesis, as also revealed by bone marrow examination of the only patient who 
received this test.6 Both young platelet count and TPO levels indicate that thrombocytopenia derives 
from defects of the latest phases of megakaryocyte maturation. Consistent with this conclusion, 
investigations in mouse megakaryocytes showed that they had defective proplatelet formation and 
platelet release when expressing ACTN1 mutants.5 
In vitro platelet aggregation in response to ADP, collagen, and ristocetin was normal and the 
expression level of glycoproteins (GP) GPIb, GPIX, GPIIb, and GPIIIa on the platelet surface was 
increased, as expected in individuals with platelet macrocytosis (Table 2S). Consistent with mild 
thrombocytopenia, as well as with platelet aggregation and expression of major platelet glycoproteins 
in the normal range, spontaneous bleeding tendency was absent or mild, with a few episodes of 
epistaxis, gum bleeding, easy bruising and menorrhagia (Table 1). Only three females received iron 
therapy for menorrhagia. Four of the 18 patients undergoing surgery had excessive bleeding, but only 
one needed platelet transfusions. Of the 30 deliveries, only one had increased blood loss. Although 
limited, these severe hemorrhagic episodes suggest caution when hemostatic challenges occurs. 
Finally, we did not observe additional phenotypic defects consistently associated with ACTN1 
mutations. However, it is worth mentioning that three individuals from family 2, whose genotypes 
and platelet counts were not available, developed leukemia (both age of onset and type of leukemia 
were not available) (Figure 1S). Moreover, individuals from families 1 and 5 had mitral valve prolapse 
(MVP) and/or atrial sept defect (ASD) (Figure 1S). Since one individual with ASD (family 5) did not 
carry the mutation (p.Gly251Arg) segregating with thrombocytopenia in his family, a gene other than 
ACTN1 is likely to be responsible at least for this heart malformation. Since the search for cardiac 
anomalies was not systematically performed in our case series, we cannot exclude that other subjects 
with ACTN1-RT had similar defects. Hence, echocardiography may be appropriate in this form of IT. 
 
  
ACTN1-RT is relatively common among the different forms of IT at least in Italy and Japan. 5 Indeed, 
we identified ACTN1 mutations in 10 of 239 (4.2%) consecutive IT families, a frequency similar to that 
reported in the Japanese population (3.7%).5 Considering only the ITs with large platelets, the 
frequency is 6.6% in our population. However, we cannot exclude that ACTN1-RT is more frequent 
than expected, because affected subjects have no pathognomonic features and may be easily 
misdiagnosed as having immune thrombocytopenia.12 Four of our patients had this diagnosis and 
three were treated with steroids without any effect on platelet count. Therefore, molecular genetic 
testing, combined with segregation analysis and functional assays carried out to discriminate between 
pathogenic and silent variants, is the only diagnostic approach to identify patients with ACTN1-RT. 
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Figure Legend 
 
Figure 1. Functional studies of novel ACTN1 variants. (A) Immunofluorescence analysis in PD220 
fibroblast cell line transiently transfected according to standard procedures. Both wild type (top 
panel) or mutant (lower panels) ACTN1 cDNAs were cloned into the pcDNA3.1-Myc tagged expression 
vector.5 The subcellular localization of exogenous -actinin1 (green) was examined using c-myc 
antibodies (9E10; Santa Cruz Biotechnology, Dallas, Texas, U.S.A.) while the actin filaments were 
stained with AlexaFluor594 (red) conjugated phalloidin (Invitrogen, Marseille, France). Images were 
obtained with a Nikon C1si confocal microscope using a 60X Plan Apo objectives. Images were 
processed for z-projection (maximum intensity), brightness and contrast regulation using ImageJ 1.45 
(NIH, Bethesda, USA). The cells shown are representative of three independent experiments. Scale 
bar =50 µm. (B) Domain structure of actinin and localization of ACTN1 mutations identified in 
Japanese families (arrowheads)5 and in this paper (arrows). The p.Arg46Gln mutation was also 
identified in a French family.6 -actinin is organized in an actin binding domain (ABD) at the N-
terminus, four spectrin repeats and a calmodulin-like domain (CaM) at the C-terminus. Antiparallel 
molecules dimerize in rod-like structures with the ABD at each extremity for cross-linking the actin 
filaments into bundles.  
 
  
 
Table 1. Features of families with ACTN1 mutations 
Family 
(N. of 
individuals) 
Mean age at 
diagnosis 
Years range 
WHO bleeding 
scorea 
Mean platelet 
countb,c 
x109/L range 
Mean platelet 
volumeb 
fL range 
Mean platelet 
diameterd 
m range 
ACTN1 
mutation 
F1 (4) 
43 
22-55 0 (1), 1 (3) 107 89-134 11.1 10.1-12.0 2.8 2.7-3.0 p.Asp22Asn 
F2 (4) 
46 
26-64 0 (1), 1 (2), 2 (1) 103 81-118 12.5 10.6-14.7 3.3 3.0-3.7 p.Arg46Trp 
F3 (4) 
42 
14-72 0 (1), 1 (1), 2 (2) 95 66-124 14.8 14.0-15.6 3.8 3.5-4.1 p.Arg46Trp 
F4 (2) 
30 
12-49 0 (2) 103 97-110 11.8 11.3-12.4 3 2.8-3.1 p.Glu225Lys 
F5 (6) 
23 
7-44 0 (1), 1 (3), 2 (3) 103 78-154 12.3 10.4-14.0 3.3 2.6-4.3 p.Gly251Arg 
F6 (2) 
58 
34-82 2 (2) 58 55-62 10.5 10.4-10.6 3.2 2.9-3.5 p.Thr737Asn 
F7 (1) nd 0 (1) 110 12.1 2.5 p.Arg738Trp 
F8 (3) 
25 
3-44 0 (2), 1 (1) 112 65-166 12.5 11.3-14.3 2.8 2.6-3.0 p.Arg752Gln 
F9 (1) 48 0 (1) 117 14.4 3.3 p.Gly764Ser 
F10 (4) 
38 
3-66 0 (1), 1 (2), 2 (1) 86 46-120 14-3 12.6-15 3.5 2.9-3.9 p.Glu769Lys 
aWHO (World Health Organization) bleeding score: grade 0, no bleeding; grade 1, only cutaneous bleeding; grade 2, mild blood loss; 
grade 3, gross blood loss, requiring transfusion; grade 4, debilitating blood loss, retinal or cerebral associated with fatality. 
bPlatelet count and mean platelet volume were measured with a Cell-Dyn Sapphire hematology analyzer (Abbott, Lake Forest, IL, USA) in 
EDTA-anticoagulated blood samples within one hour from venipuncture.  
cOne individual from family 5 and 8 with more than 150 x 109 platelets/L (bold) were classified as thrombocytopenic according to the 
recently proposed age- and gender specific reference intervals.19  
dMean platelet diameter was measured on peripheral blood films by optical microscopy and software-assisted image analysis (Axio-vision 
4.5; Carl Zeiss, Göttingen, Germany) as previously reported.17 In brief, blood smears prepared with non-anticoagulated blood from 
fingerstick were stained with May-Grünwald-Giemsa staining and the mean platelet diameter was calculated from 200 different cell. 
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Table 1S. Variants identified in the ACTN1 gene. 
 
cDNA
a,b
 Exon Protein 
Bioinformatic analysis
c
 
Segregation 
(Family)
d
 
Cytoskeleton 
organization
e
 
References 
PlyPhen-2 SIFT Mutation Taster 
c.64G>A 1 p.Asp22Asn Possibly damaging Not tolerated Disease causing Yes (F1) Altered This study 
c.136C>T 2 p.Arg46Trp Probably damaging Not tolerated Disease causing Yes (F2, F3) Altered This study 
c.673G>A 7 p.Glu225Lys Possibly damaging Not tolerated Disease causing Yes (F4) Altered This study 
c.751G>A 8 p.Gly251Arg Possibly damaging Not tolerated Disease causing Yes (F5) Altered This study 
c.1997A>T 17 p.Asp666Val Probably damaging Not tolerated Disease causing No Normal This study 
c.2210C>A 18 p.Thr737Asn Possibly damaging Not tolerated Disease causing Yes (F6) Altered This study 
c.2212C>T 18 p.Arg738Trp Probably damaging Not tolerated Disease causing nd (F7) nd Kunishima et al. 2013
1
 
c.2255G>A 18 p.Arg752Gln Probably damaging Not tolerated Disease causing Yes (F8) nd Kunishima et al, 2013
1
 
c.2290G>A 19 p.Gly764Ser Possibly damaging Tolerated Disease causing nd (F9) Altered This study 
c.2305G>A (WES)
f
 19 p.Glu769Lys Benign Not tolerated Disease causing Yes (F10) Altered This study 
a
Nucleotide A of the ATG translation initiation start site of the ACTN1 cDNA in GenBank sequence NM_001130004.1 is indicated as nucleotide +1. The only not pathogenetic variant is 
indicated in bold. 
b
All but one (c.2305G>A) the mutations were identified by Sanger sequencing of the ACTN1 gene. The analysis was restricted to exons encoding for the N-terminus actin binding domain (ABD; 
exons 1-8) and for the C-terminus calmodulin-like domain (CaM; exons 17-21), where mutations were previously identified.
1,2
 PCR products was obtained using standard protocols  according 
to standard protocols and sequenced using the 3130xl Genetic Sequencer (Applied Biosystems, Foster City, CA). 
c
Effect of variations was evaluated using three pathogenicity prediction programs: PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http:// http://sift.jcvi.org/), and Mutation 
Taster (http://www.mutationtaster.org/). 
d
For  segregation analysis in families see Figure 1S. 
e
For deleterious effects of mutations on cytoskeleton organization see Figure 1. 
f
Whole exome sequencing (WES) was performed using the solid-phase NimbleGen SeqCap EZ Exome 44Mb array (Nimblegen Inc., Madison, WI, USA) and sequenced as 91/100 bp paired-end 
reads on Illumina HiSeq2000 platform (Illumina Inc., San Diego, CA, USA). Variants passing quality filters were annotated using ANNOVAR
15
 against NCBI RefGene 
(http://www.ncbi.nlm.nih.gov). Variants of the ACTN1 gene were confirmed by Sanger sequencing as above. Variants were confirmed by Sanger sequencing. 
Table 2S. In vitro platelet aggregation and flow cytometry of platelet glycoproteins. 
 
a
Expressed as mean ± SD percentage of platelet aggregation after 5 min from the addition of ADP (5 M), ristocetin (1.5 mg/mL) (both from Sigma Chemical Co, St. Louis, MO, USA) and 
collagen (4 g/mL; Mascia Brunelli, Milan, Italy). Blood was collected in 3.8% (w/v) sodium citrate (blood:anticoagulant ratio 9:1). To minimize the loss of denser platelets, platelet-rich 
plasma (PRP) was obtained by sedimentation of the blood at 1 g for 20 to 30 min. Platelet aggregation was measured in PRP by the densitometric method of Born.
3
 
b
Expressed as mean ± SD fluorescence intensity compared to control. Flow cytometric analysis of surface platelet GP expression was performed in PRP obtained from EDTA-
anticoagulated as previously reported.
4
 The platelets were incubated with the following monoclonal antibodies: SZ2 (Immunotech, Marseille, France) or MB45 (CLB, Amsterdam, the 
NetherlaŶdsͿ for GPIďα ;CD4ϮďͿ deteĐtioŶ; “)ϭ ;IŵŵuŶoteĐhͿ for GPIX ;CD4ϮaͿ; “)Ϯϭ ;IŵŵuŶoteĐhͿ for GPIIIa ;CD6ϭͿ; PϮ ;IŵŵuŶoteĐhͿ for deteĐtioŶ of GPIIď ;αIIďͿ wheŶ ĐorreĐtly 
complexed with GPIIIa. The negative control MO2 and fluorescein isothiocyanate-conjugated goat anti-mouse IgG (GAM-FITC) were purchased from Coulter Corporation, Miami, USA. 
Fluorescent antibody staining of the platelets was analyzed with the FC500 flow cytometer (Beckman Coulter, Brea, California, U.S.). Ten thousand platelet events were collected and 
the value of mean fluorescence, expressed in arbitrary units, was recorded. Results were expressed as % of the values obtained in control samples analyzed in parallel. The same 
control was used for all patients.
Family 
In vitro platelet aggregation
a
 
 (N. of patients) 
Flow cytometry of platelet glycoproteins (GP)
b
 
 (N. of patients) 
ADP Collagen  Ristocetin GPIba GPIX GPIIIa GPIIb 
F1  nd 98 ± 21 (4) 124 ± 8 (4) 94 ± 7 (4) 115 ± 17 (4) 
F2  92 ± 10 (4) 90 ± 8 (4) 96 ± 5 (4) 121 ± 32 (4) 142 ± 37 (4) 108 ± 25 (4) 136 ± 21 (4) 
F3  68 ± 11 (4) 83 ± 13 (4) 90 ± 10 (4) 154 ± 6 (3) 136 ± 29 (3) 114 ± 6 (3) 120 ± 24 (3) 
F4  75 ± 7 (2) 77 ± 4 (2) 88 ± 3 (2) 182 (1) 174 (1) 138 (1) 134 (1) 
F5  90 ± 2 (2) 94 ± 4 (2) 91 ± 8 (2) 138 ± 14 (5) 134 ± 12 (5) 126 ± 26 (5) 116 ± 20 (5) 
F6 71 (1) 72 (1) 83 (1) nd 
F7  nd 
F8 nd 134 ± 24 (2) 120 ± 14 (2) 115 ± 9 (2) 112 ± 10 (2) 
F9 89 (1) 96 (1) 100 (1) 106 (1) 115 (1) 142 (1) 121 (1) 
F10 88 ± 9 (4) 94 ± 5 (4) 89 ± 11 (4) 124 ± 15 (4) 143 ± 25 (4) 127 ± 21 (4) 130 ± 12 (4) 
FIGURE 1S 
 
 
Identification of novel ACTN1 mutations. Pedigrees of eight families with heterozygous novel 
missense mutations of ACTN1. “yŵďols ͞+͟ aŶd ͞-͞ iŶdiĐate wild type and mutant alleles, respectively. 
In family members with question marks, both phenotype and genotype are unknown. Individuals with 
only thrombocytopenia are in black symbols; in those with mitral valve prolapse (MVP) and/or atrial 
sept defect (ASD), the cardiac defect is indicated below the symbol (Families 1 and 5). In Family 2, 
three relatives (two nieces and one grandniece) of the first-generation affected male developed 
leukemia (not shown). Chromatogram of each mutation is shown under the corresponding pedigree. 
Families 2 and 3 share the same c.136C>T mutation. 
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